# EDGAR Filing Document

**Accession Number:** 0001787400
**File Stem:** 0001787400-26-000008
**Filing Date:** 2026-3
**Character Count:** 7727
**Document Hash:** e4a6d7642f352838fc09500ad94c2bf6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001787400-26-000008.hdr.sgml**: 20260326

**ACCESSION NUMBER**: 0001787400-26-000008

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260325

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260326

**DATE AS OF CHANGE**: 20260325

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nkarta, Inc.
- **CENTRAL INDEX KEY:** 0001787400
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474515206
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39370
- **FILM NUMBER:** 26793728

**BUSINESS ADDRESS:**
- **STREET 1:** 1150 VETERANS BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (925) 407-1049

**MAIL ADDRESS:**
- **STREET 1:** 1150 VETERANS BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported):** March 25, 2026

------

Nkarta, Inc.

**(Exact name of Registrant as Specified in Its Charter)** 

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39370 | 47-4515206 |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| 1150 Veterans Boulevard<br>South San Francisco**,** CA |  | 94080 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

------

**Registrant's Telephone Number, Including Area Code: (**925**)** 407-1049

**Not Applicable** 

**(Former Name or Former Address, if Changed Since Last Report)** 

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | NKTX<br>| Nasdaq Global Select Market<br>|

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 8.01 Other Events.**

On March 25, 2026, Nkarta, Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with Stifel, Nicolaus & Company, Incorporated ("Stifel") with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the "Common Stock"), having an aggregate offering price of up to $100,000,000 (the "Shares") through Stifel as its "sales agent" (the "Agent").

Under the Sales Agreement, the Company will set the parameters for the sale of Shares, including the number of Shares to be issued, the time period during which sales are requested to be made, limitations on the number of Shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms of the Sales Agreement, the Agent may sell the Shares by any method that is deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act, including without limitation sales made on or through the Nasdaq Global Select Market or on any other trading market for the Common Stock, in the over-the-counter market, in privately negotiated transactions or through a combination of any such methods of sale permitted by law.

The Company will pay the Agent a commission equal to up to 3% of the gross sales proceeds of any Shares sold through the Agent under the Sales Agreement, and has provided the Agent with customary indemnification and contribution rights.

The Sales Agreement will terminate upon the earlier of (i) the sale of all Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with the terms and conditions set forth therein.

Any Shares to be offered and sold under the Sales Agreement will be issued and sold pursuant to the Company's Registration Statement on Form S-3 (File No. 333-294611), which was filed with the Securities and Exchange Commission ("SEC") on March 25, 2026, and included an "at-the-market offering" prospectus supplement relating to the offer and sale of the Shares filed with the SEC on March 25, 2026.

The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is attached as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

O'Melveny & Myers LLP, counsel to the Company, has issued an opinion to the Company, dated March 25, 2026, relating to the validity of the Shares to be issued and sold pursuant to the Sales Agreement, a copy of which is filed as Exhibit 5.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 1.1# | [<u>Sales Agreement (incorporated by reference to Exhibit 1.2 to Nkarta, Inc.'s Registration Statement on Form S-3 (No. 333-294611) filed with the SEC on March 25, 2026)</u>](https://www.sec.gov/Archives/edgar/data/1787400/000114036126011152/ny20068088x1_ex1-2.htm) |
| 5.1 | [<u>Opinion of O'Melveny & Myers LLP (incorporated by reference to Exhibit 5.2 to Nkarta, Inc.'s Registration Statement on Form S-3 (No. 333-294611) filed with the SEC on March 25, 2026)</u>](https://www.sec.gov/Archives/edgar/data/1787400/000114036126011152/ny20068088x1_ex5-2.htm) |
| 23.1 | [<u>Consent of O'Melveny & Myers LLP (contained in Exhibit 5.1)</u>](https://www.sec.gov/Archives/edgar/data/1787400/000114036126011152/ny20068088x1_ex5-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

# Certain personally identifiable information of this exhibit has been omitted pursuant to Item 601(a)(6) of Regulation S-K

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Nkarta, Inc. | Nkarta, Inc. |
| Date: March 25, 2026 | By: | /s/ Nadir Mahmood |
|  |  | **Nadir Mahmood** |
|  |  | **President** |

---

------